恒瑞医药(01276)：阿得贝利单抗注射液获批新增非小细胞肺癌(NSCLC)围术期适应症

智通财经06-25

智通财经APP讯，恒瑞医药(01276)公布，近日，公司子公司上海盛迪医药有限公司收到国家药品监督管理局的通知，批准公司阿得贝利单抗注射液新增非小细胞肺癌(NSCLC)围术期适应症，这是阿得贝利单抗在肺癌领域获批的第二项适应症，也由此成为国内首个获批 NSCLC 围术期适应症的国产 PD-L1 抑制剂。

阿得贝利单抗注射液已于 2023 年 2 月获批上市，获批的适应症为与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2646803381?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-25 20:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646803381","market":"sh","top_or_hot":-1,"title":"恒瑞医药(01276)：阿得贝利单抗注射液获批新增非小细胞肺癌(NSCLC)围术期适应症","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/600276\">恒瑞医药</a>(01276)公布，近日，公司子公司上海盛迪医药有限公司收到国家药品监督管理局的通知，批准公司阿得贝利单抗注射液新增非小细胞肺癌(NSCLC)围术期适应症，这是阿得贝利单抗在肺癌领域获批的第二项适应症，也由此成为国内首个获批 NSCLC 围术期适应症的国产 PD-L1 抑制剂。</p><p>阿得贝利单抗注射液已于 2023 年 2 月获批上市，获批的适应症为与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药(01276)：阿得贝利单抗注射液获批新增非小细胞肺癌(NSCLC)围术期适应症</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药(01276)：阿得贝利单抗注射液获批新增非小细胞肺癌(NSCLC)围术期适应症\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/600276\">恒瑞医药</a>(01276)公布，近日，公司子公司上海盛迪医药有限公司收到国家药品监督管理局的通知，批准公司阿得贝利单抗注射液新增非小细胞肺癌(NSCLC)围术期适应症，这是阿得贝利单抗在肺癌领域获批的第二项适应症，也由此成为国内首个获批 NSCLC 围术期适应症的国产 PD-L1 抑制剂。</p><p>阿得贝利单抗注射液已于 2023 年 2 月获批上市，获批的适应症为与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1458985.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2580892789.USD","symbol_name":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1458985.html","article_id":"2646803381","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646803381","pubTimestamp":1782392219,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，恒瑞医药(01276)公布，近日，公司子公司上海盛迪医药有限公司收到国家药品监督管理局的通知，批准公司阿得贝利单抗注射液新增非小细胞肺癌(NSCLC)围术期适应症，这是阿得贝利单抗在肺癌领域获批的第二项适应症，也由此成为国内首个获批 NSCLC 围术期适应症的国产 PD-L1 抑制剂。阿得贝利单抗注射液已于 2023 年 2 月获批上市，获批的适应症为与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU1997245177.USD":"安联神洲A股基金","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0183":"MSCI概念","BK0188":"融资融券","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK0012":"证金概念","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0028":"国家队","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK1191":"制药","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0060":"抗癌","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","01276":"恒瑞医药","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0196":"行业龙头","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","BK0239":"医药制造","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC"},"translate_title":"Hengrui Medicine (01276): Adebelimab injection approved for new perioperative indications for non-small cell lung cancer (NSCLC)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"01276":1.5},"content_text":"智通财经APP讯，恒瑞医药(01276)公布，近日，公司子公司上海盛迪医药有限公司收到国家药品监督管理局的通知，批准公司阿得贝利单抗注射液新增非小细胞肺癌(NSCLC)围术期适应症，这是阿得贝利单抗在肺癌领域获批的第二项适应症，也由此成为国内首个获批 NSCLC 围术期适应症的国产 PD-L1 抑制剂。阿得贝利单抗注射液已于 2023 年 2 月获批上市，获批的适应症为与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646803381","isCrawlerRequest":true}